{"preliminary_commentary":{"by_channel":{"x_thread":21,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04853017\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"AMPLIFY-201","nct_id":"NCT04853017","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=amplify-201-nct04853017. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"AMPLIFY-201","arms":[{"description":"ELI-002 2P Amph-CpG-7909 (0.1 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via subcutaneous (SC) injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)","label":"ELI-002 2P Cohort 1","type":"EXPERIMENTAL"},{"description":"ELI-002 2P Amph-CpG-7909 (0.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)","label":"ELI-002 2P Cohort 2","type":"EXPERIMENTAL"},{"description":"ELI-002 2P Amph-CpG-7909 (2.5 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)","label":"ELI-002 2P Cohort 3","type":"EXPERIMENTAL"},{"description":"ELI-002 2P Amph-CpG-7909 (5.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)","label":"ELI-002 2P Cohort 4","type":"EXPERIMENTAL"},{"description":"ELI-002 2P Amph-CpG-7909 (10.0 mg) admixed with Amph modified KRAS peptides (Amph-G12D and Amph-G12R) administered via SC injection weekly for 4 consecutive weeks, followed by bi-weekly injections over 4 weeks, during the Immunization period; additional SC injections weekly for 4 consecutive weeks during the Booster Period (the two periods are separated by 3 months of no dosing)","label":"ELI-002 2P Cohort 5","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-09-24","type":"ACTUAL"},"conditions":["Minimal Residual Disease","KRAS G12D","KRAS G12R","NRAS G12D","NRAS G12R","Pancreatic Ductal Adenocarcinoma","Colorectal Cancer","Non-small Cell Lung Cancer","Ovarian Cancer","Cholangiocarcinoma","Bile Duct Cancer","Gallbladder Carcinoma"],"enrollment":{"count":25,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"ELI-002 2P","otherNames":[],"type":"DRUG"}],"last_update":"2025-09-05","lead_sponsor":"Elicio Therapeutics","official_title":"First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid Tumors","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2023-01-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"The Participant Incidence of Treatment-emergent Adverse Events Considered by the Investigator as Related to ELI-002","timeFrame":"Adverse events were collected through 28 days after the last dose"}],"references":[{"citation":"Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, Pant S, O'Reilly EM. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nat Med. 2025 Nov;31(11):3648-3653. doi: 10.1038/s41591-025-03876-4. Epub 2025 Aug 11.","pmid":"40790272","type":"DERIVED"},{"citation":"Pant S, Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Basturk O, VanWyk H, Tavares AM, Seenappa LM, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq CM, O'Reilly EM. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024 Feb;30(2):531-542. doi: 10.1038/s41591-023-02760-3. Epub 2024 Jan 9.","pmid":"38195752","type":"DERIVED"}],"start_date":{"date":"2021-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04853017"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/amplify-201-nct04853017"}